Marija Kukuric
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Marija Kukuric has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Dušan Spasić
Department of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia
3 shared publications - Milica Bajcetic
Department of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia
3 shared publications - Deana Medic
Department of Microbiology with Parasitology and Immunology, Faculty of Medicine, University of Novi Sad, 21000 Novi Sad, Serbia
1 shared publication - Jovana Joksimovic
Human Medicines Centre, Medicines and Medical Devices Agency of Serbia (ALIMS), 11221 Belgrade, Serbia
1 shared publication - Lidija Stanic
Clinic for Neurosurgery, University Clinical center of Serbia, Koste Todorovica 4, 11000 Belgrade, Serbia
1 shared publication - Vojislav Bogosavljevic
Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia
1 shared publication
Latest Publications
- Open Access
- 16 July 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (7) , 694
Antibiotic Resistance Profiles of Invasive Bacterial Isolates from Hospitalized Pediatric Patients in Serbia: A Multicenter Surveillance Study, 2020–2024
Background: Antimicrobial resistance (AMR) threatens empirical therapy for invasive pediatric infections, but contemporary data from Serbia and the Western Balkans remain limited for blood and cerebrospinal fluid isolates. Methods: We performed a retrospective CAESAR-linked multicenter microbiological surveillance analysis of first eligible invasive bacterial isolates from hospitalized children in Serbia from 1 January 2020 to 31 December 2024. Organism distribution, ESBL production, carbapenemase marker results, and selected resistance outcomes were analyzed descriptively and with temporal trend and multivariable models. Results: Among 907 isolates, 879 (96.9%) were recovered from blood and 28 (3.1%) from cerebrospinal fluid; neonates and infants accounted for 57.9% of isolates. K. pneumoniae was the predominant organism (318/907, 35.1%), followed by E. coli (172/907, 19.0%), S. aureus (137/907, 15.1%), and Acinetobacter spp. (96/907, 10.6%). Among K. pneumoniae and E. coli isolates with available ESBL results, ESBL production was frequent, whereas carbapenemase testing was restricted to a selected subset and the carbapenemase type was not recorded in the national surveillance extract. In K. pneumoniae, meropenem resistance increased from 19.7% in 2020 to 48.6% in 2024, and later study years remained independently associated with meropenem resistance after adjustment. Conclusions: This microbiological surveillance study identifies K. pneumoniae predominance, neonatal concentration, frequent ESBL production, and a rising carbapenem-resistance signal as the principal findings among invasive pediatric isolates in Serbia. Resistance estimates, particularly carbapenemase production, should be interpreted as surveillance indicators rather than clinical prevalence estimates. These data support strengthened pediatric invasive-isolate surveillance, center- and age-specific antibiograms, molecular characterization, and coordinated antimicrobial stewardship and infection prevention and control efforts within the wider European AMR context.
- 16 July 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (7) , 694
Open AccessAntibiotic Resistance Profiles of Invasive Bacterial Isolates from Hospitalized Pediatric Patients in Serbia: A Multicenter Surveillance Study, 2020–2024
Background: Antimicrobial resistance (AMR) threatens empirical therapy for invasive pediatric infections, but contemporary data from Serbia and the Western Balkans remain limited for blood and cerebrospinal fluid isolates. Methods: We performed a retrospective CAESAR-linked multicenter microbiological surveillance analysis of first eligible invasive bacterial isolates from hospitalized children in Serbia from 1 January 2020 to 31 December 2024. Organism distribution, ESBL production, carbapenemase marker results, and selected resistance outcomes were analyzed descriptively and with temporal trend and multivariable models. Results: Among 907 isolates, 879 (96.9%) were recovered from blood and 28 (3.1%) from cerebrospinal fluid; neonates and infants accounted for 57.9% of isolates. K. pneumoniae was the predominant organism (318/907, 35.1%), followed by E. coli (172/907, 19.0%), S. aureus (137/907, 15.1%), and Acinetobacter spp. (96/907, 10.6%). Among K. pneumoniae and E. coli isolates with available ESBL results, ESBL production was frequent, whereas carbapenemase testing was restricted to a selected subset and the carbapenemase type was not recorded in the national surveillance extract. In K. pneumoniae, meropenem resistance increased from 19.7% in 2020 to 48.6% in 2024, and later study years remained independently associated with meropenem resistance after adjustment. Conclusions: This microbiological surveillance study identifies K. pneumoniae predominance, neonatal concentration, frequent ESBL production, and a rising carbapenem-resistance signal as the principal findings among invasive pediatric isolates in Serbia. Resistance estimates, particularly carbapenemase production, should be interpreted as surveillance indicators rather than clinical prevalence estimates. These data support strengthened pediatric invasive-isolate surveillance, center- and age-specific antibiograms, molecular characterization, and coordinated antimicrobial stewardship and infection prevention and control efforts within the wider European AMR context.
- Open Access
Serious Adverse Drug Reactions Associated with Off-Label and Unlicensed Drug Use in Children: A 14-Year Analysis of VigiBase Reports from Serbia
Background/Objectives: Adverse drug reactions are associated with off-label (OL) and unlicensed (UL) drug use in children. Methods: We conducted a retrospective observational pharmacovigilance study based on individual case safety reports (ICSRs) and adverse drug reactions (ADRs) from VigiBase for patients aged 0–17 years to evaluate reporting patterns associated with off-label and unlicensed suspected drugs reported in Serbia. Results: Over 14 years, 2037 pediatric ICSRs comprising 4257 ADRs were reported. Infants (28 days–23 months) accounted for just over half of ICSRs, and systemic anti-infectives and vaccines dominated suspected drugs. Overall, 9.7% of ADRs were serious, including 12 fatal outcomes, with serious ADRs reported more often for non-vaccine than vaccine suspected drugs. Off-label and unlicensed suspected drug records accounted for 10.8% and 1.9% of suspected drug records, respectively, and had higher proportions of serious ADRs than on-label or licensed use (off-label 12.1% vs. on-label 9.4%, p = 0.04; unlicensed 22.9% vs. licensed 9.4%, p < 0.001). In the adjusted ICSR-level logistic regression, neonatal age was the strongest independent predictor of seriousness, with approximately threefold higher odds of a serious case compared with children (aOR 3.04, 95% CI 1.55–5.98). Conclusions: Although off-label and unlicensed drugs accounted for a minority of pediatric reports, they were associated with a higher proportion of serious reported ADRs, particularly in the neonatal period. These findings should be interpreted as pharmacovigilance reporting patterns rather than incidence-based estimates or proof of causality.
Open AccessSerious Adverse Drug Reactions Associated with Off-Label and Unlicensed Drug Use in Children: A 14-Year Analysis of VigiBase Reports from Serbia
Background/Objectives: Adverse drug reactions are associated with off-label (OL) and unlicensed (UL) drug use in children. Methods: We conducted a retrospective observational pharmacovigilance study based on individual case safety reports (ICSRs) and adverse drug reactions (ADRs) from VigiBase for patients aged 0–17 years to evaluate reporting patterns associated with off-label and unlicensed suspected drugs reported in Serbia. Results: Over 14 years, 2037 pediatric ICSRs comprising 4257 ADRs were reported. Infants (28 days–23 months) accounted for just over half of ICSRs, and systemic anti-infectives and vaccines dominated suspected drugs. Overall, 9.7% of ADRs were serious, including 12 fatal outcomes, with serious ADRs reported more often for non-vaccine than vaccine suspected drugs. Off-label and unlicensed suspected drug records accounted for 10.8% and 1.9% of suspected drug records, respectively, and had higher proportions of serious ADRs than on-label or licensed use (off-label 12.1% vs. on-label 9.4%, p = 0.04; unlicensed 22.9% vs. licensed 9.4%, p < 0.001). In the adjusted ICSR-level logistic regression, neonatal age was the strongest independent predictor of seriousness, with approximately threefold higher odds of a serious case compared with children (aOR 3.04, 95% CI 1.55–5.98). Conclusions: Although off-label and unlicensed drugs accounted for a minority of pediatric reports, they were associated with a higher proportion of serious reported ADRs, particularly in the neonatal period. These findings should be interpreted as pharmacovigilance reporting patterns rather than incidence-based estimates or proof of causality.
- Open Access
- 5 October 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (10) , 996
Does Vancomycin as the First-Choice Therapy for Antibiotic Prophylaxis Increase the Risk of Surgical Site Infections Following Spine Surgery?
Surgical site infections (SSIs) remain a significant complication in spine surgery, especially in instrumented procedures with long operative times. Although guidelines recommend cefazolin as the first-line agent due to its efficacy against Staphylococcus aureus, predictable pharmacokinetics, and safety, its real-world practice is highly variable, with inappropriate and prolonged regimens reported across Europe. Vancomycin is often used as the first choice of therapy empirically and without screening, exposing patients to risks such as delayed infusion, nephrotoxicity, and the emergence of vancomycin-resistant enterococci (VRE).This review assesses the present function of vancomycin in relation to cefazolin for spinal prophylaxis and examines wider trends in the misuse of surgical antibiotic prophylaxis, which were identified through PubMed and Scopus searches. Evidence from randomized and prospective studies consistently supports cefazolin as the preferred prophylactic agent in clean spinal surgery. Observational data suggest that adjunctive or topical vancomycin may reduce infection rates in selected high-risk or revision cases, though the results are inconsistent and frequently limited by retrospective designs and heterogeneous outcome reporting. Importantly, the most rigorous randomized controlled trial found no benefit of intrawound vancomycin over the placebo. A small number of available investigations in vancomycin use with major design limitations have resulted in no significant VRE emergency. Unexpectedly, widespread use of vancomycin was followed by a notable transition toward Gram-negative and opportunistic organisms. In summary, vancomycin may only be considered in patients with documented MRSA colonization, β-lactam allergy, or selected revision procedures, but its widespread empirical use as a first-choice therapy is not supported.
- 5 October 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (10) , 996
Open AccessDoes Vancomycin as the First-Choice Therapy for Antibiotic Prophylaxis Increase the Risk of Surgical Site Infections Following Spine Surgery?
Surgical site infections (SSIs) remain a significant complication in spine surgery, especially in instrumented procedures with long operative times. Although guidelines recommend cefazolin as the first-line agent due to its efficacy against Staphylococcus aureus, predictable pharmacokinetics, and safety, its real-world practice is highly variable, with inappropriate and prolonged regimens reported across Europe. Vancomycin is often used as the first choice of therapy empirically and without screening, exposing patients to risks such as delayed infusion, nephrotoxicity, and the emergence of vancomycin-resistant enterococci (VRE).This review assesses the present function of vancomycin in relation to cefazolin for spinal prophylaxis and examines wider trends in the misuse of surgical antibiotic prophylaxis, which were identified through PubMed and Scopus searches. Evidence from randomized and prospective studies consistently supports cefazolin as the preferred prophylactic agent in clean spinal surgery. Observational data suggest that adjunctive or topical vancomycin may reduce infection rates in selected high-risk or revision cases, though the results are inconsistent and frequently limited by retrospective designs and heterogeneous outcome reporting. Importantly, the most rigorous randomized controlled trial found no benefit of intrawound vancomycin over the placebo. A small number of available investigations in vancomycin use with major design limitations have resulted in no significant VRE emergency. Unexpectedly, widespread use of vancomycin was followed by a notable transition toward Gram-negative and opportunistic organisms. In summary, vancomycin may only be considered in patients with documented MRSA colonization, β-lactam allergy, or selected revision procedures, but its widespread empirical use as a first-choice therapy is not supported.